---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-209259"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:08:07.626672+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025

## Summary
- Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.
- Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.
- No successor or interim CSO announced; departure of named executive officer.

## SEC filing metadata
- accession: 0001193125-25-209259
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/0001193125-25-209259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312525209259/janx-20250918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-209259
- JSON: https://secwatch.observer/filing/0001193125-25-209259.json
- Plain text: https://secwatch.observer/filing/0001193125-25-209259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.